Next-Generation Mouse Models: Tau Knock-ins and Human Chimeras
At SfN 2016, researchers debuted new mouse models that may better represent human disease.
6397 RESULTS
Sort By:
At SfN 2016, researchers debuted new mouse models that may better represent human disease.
Where does TREM2-dependent microglial activity fit into the staging diagram of Alzheimer’s disease?
Researchers at SfN 2016 reported that oligomeric and exosomal forms in plasma predict AD as early as a decade prior to symptoms.
CTAD: Solanezumab Seen to Nudge AD Ever so Slightly Tau Inhibitor Fails Again—Subgroup Analysis Irks Clinicians at CTAD Much ‘Adu’ About a Little: Phase 1 Data Feeds the Buzz at CTAD Tau PET in Down’s: Unique Patterns Among Alzheimer’s Types and Stages Em
The tau aggregation inhibitor LMTM tanks in second Phase 3 trial for Alzheimer’s. The sponsor now plans to develop the “placebo.”
Scientists at SfN presented innovative ways to slow amyloid accumulation and preserve synapses.
Cognitively normal people who harbor plaques in their brains are more likely to report feelings of isolation.
Sanofi Genzyme will test a compound currently in development for Gaucher’s disease in Parkinson’s patients who carry a glucocerebrosidase (GBA) mutation.
Biogen and Genentech rolled out more data from their Phase 1b trials, renewing hope that amyloid removal will work and shoring up dosing for Phase 3.
At CTAD, tau PET data from people in different stages of various neurodegenerative diseases highlighted both commonalities and peculiarities.
Diurnal variations disappear as less Aβ42 reaches cerebrospinal fluid. Findings may improve timing of daily amyloid treatments.
Alzforum reviews the major newsmakers of the past 12 months.
The finding could help researchers develop safer, more effective immunotherapies, and might apply to other types of protein aggregates as well, scientists said.
By fusing disordered protein regions to a plant photoreceptor, scientists study how RNA-binding proteins form liquid droplets within the cytoplasm, and what leads these structures to spawn potentially toxic aggregates.
Three cytokines released by activated immune cells in the brain turn astrocytes into neuron-killing machines.